Two Sigma Securities LLC Sells 11,642 Shares of Humana Inc. (NYSE:HUM)

Two Sigma Securities LLC decreased its stake in shares of Humana Inc. (NYSE:HUM) by 66.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,781 shares of the insurance provider’s stock after selling 11,642 shares during the quarter. Two Sigma Securities LLC’s holdings in Humana were worth $1,467,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Virtu Financial LLC bought a new position in Humana in the third quarter worth approximately $631,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Humana during the third quarter worth approximately $948,000. Tidal Investments LLC lifted its holdings in shares of Humana by 38.4% in the 3rd quarter. Tidal Investments LLC now owns 24,357 shares of the insurance provider’s stock worth $7,715,000 after purchasing an additional 6,755 shares in the last quarter. Synovus Financial Corp grew its position in Humana by 4.1% in the 3rd quarter. Synovus Financial Corp now owns 2,254 shares of the insurance provider’s stock valued at $714,000 after purchasing an additional 89 shares during the period. Finally, Oddo BHF Asset Management Sas bought a new stake in Humana during the 3rd quarter valued at $1,306,000. Institutional investors own 92.38% of the company’s stock.

Analyst Upgrades and Downgrades

HUM has been the topic of a number of recent research reports. Guggenheim began coverage on shares of Humana in a research note on Wednesday, April 9th. They issued a “buy” rating and a $326.00 price objective on the stock. Robert W. Baird raised their price target on shares of Humana from $270.00 to $300.00 and gave the company a “neutral” rating in a research report on Tuesday, April 15th. Piper Sandler boosted their price objective on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. Cantor Fitzgerald restated a “neutral” rating and issued a $290.00 target price on shares of Humana in a report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. decreased their price target on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Seventeen analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $284.90.

Humana Trading Up 1.5 %

NYSE:HUM opened at $267.47 on Friday. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The stock’s fifty day moving average price is $266.22 and its two-hundred day moving average price is $270.36. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market cap of $32.28 billion, a P/E ratio of 26.88, a P/E/G ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM) last issued its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.32%. The ex-dividend date of this dividend is Friday, June 27th. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.